Abstract
Objective To evaluate differences by race/ethnicity in clinical characteristics and outcomes among hospitalized patients with Covid-19 at Massachusetts General Hospital (MGH).
Methods The MGH Covid-19 Registry includes confirmed SARS-CoV-2-infected patients hospitalized at MGH and is based on manual chart reviews and data extraction from electronic health records (EHRs). We evaluated differences between White/Non-Hispanic and Hispanic patients in demographics, complications and 14-day outcomes among the N=866 patients hospitalized with Covid-19 from March 11, 2020 – May 4, 2020.
Results Overall, 43% of patients hospitalized with Covid-19 were women, median age was 60.4 [IQR=(48.2, 75)], 11.3% were Black/non-Hispanic and 35.2% were Hispanic. Hispanic patients, representing 35.2% of patients, were younger than White/non-Hispanic patients [median age 51y; IQR=(40.6, 61.6) versus 72y; (58.0, 81.7) (p< 0.001)]. Hispanic patients were symptomatic longer before presenting to care (median 5 vs 3d, p=0.039) but were more likely to be sent home with self-quarantine than be admitted to hospital (29% vs 16%, p< 0.001). Hispanic patients had fewer comorbidities yet comparable rates of ICU or death (34% vs 36%). Nonetheless, a greater proportion of Hispanic patients recovered by 14 days after presentation (62% vs 45%, p< 0.001; OR=1.99, p=0.011 in multivariable adjusted model) and fewer died (2% versus 18%, p< 0.001).
Conclusions Hospitalized Hispanic patients were younger and had fewer comorbidities compared to White/non-Hispanic patients; despite comparable rates of ICU care or death, a greater proportion recovered. These results have implications for public health policy and the design and conduct of clinical trials.
Competing Interest Statement
SAL receives sponsored research support from Bristol Myers Squibb / Pfizer, Bayer AG, Boehringer Ingelheim, and Fitbit, and has consulted for Bristol Myers Squibb / Pfizer and Bayer AG. SAL also participates in a research collaboration with IBM. JH reports personal fees from Cambridge Health Alliance, Community Servings, Columbia University, DaVita, University of Southern California, and from Delta Health Alliance, outside the submitted work. All other authors declare no conflicts of interest.
Funding Statement
The MGH COVID-19 Registry was supported by the MGH Division of Clinical Research and the Weissman Family MGH Research Scholar Award. The work was also supported by the National Institutes of Health R37AI058736-16S1, NIGMS R01GM127862, NHLBI R01HL132786, and NIA R01AG062393.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The MGH Covid registry was approved by the Partners HealthCare Institutional Review Board (Protocol #2020P000829). Because this work was limited to chart review, individual consent was not obtained.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available by request to ibassett{at}partners.org with appropriate permissions;.
